Key result
Infusion of the PDE1 inhibitor 8-methoxymethyl 3-isobutyl-1-methylxanthine reversed pulmonary artery pressure elevation, structural remodeling, and right heart hypertrophy in PAH animal models.
Why the study?
Does PDE1 inhibition reverse structural lung vascular remodeling and right heart hypertrophy in animal models of pulmonary hypertension?
Population
Explanted lungs from idiopathic pulmonary arterial hypertension patients, chronically hypoxic mice, and…
Design
Preclinical
Authors
Loading...
PDE1 inhibition merits exploration as a PAH target; hypothesis-generating in animals and leaves open translation to patients.
Does PDE1 inhibition reverse structural lung vascular remodeling and right heart hypertrophy in animal models of pulmonary hypertension?
PDE1 is upregulated in PAH, and its inhibition reverses vascular remodeling and right heart hypertrophy in animal models, identifying it as a potential novel therapeutic target.
Schermuly et al. (2007) studied Pulmonary arterial hypertension. 8-methoxymethyl 3-isobutyl-1-methylxanthine was evaluated on Pulmonary artery pressure elevation, structural remodeling of the lung vasculature, and right heart hypertrophy. Infusion of the PDE1 inhibitor 8-methoxymethyl 3-isobutyl-1-methylxanthine reversed pulmonary artery pressure elevation, structural remodeling, and right heart hypertrophy in PAH animal models.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: